TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Mylan (MYL) which are due to be released on Wednesday after the markets close. "The generics are under fire and I think that can end eventually but that's the weak link in the entire drug segment," Cramer said, adding that the government is scrutinizing drug price increases. Analysts expect earnings of $1.45 a share on sales of $3.12 billion. During the same quarter a year ago, the drug maker reported earnings of $1.43 a share on sales of $2.71 billion.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.